Skip to content

KIORA PHARMACEUTICALS, INC.: 10-Q filed 2026-08-07

What KIORA PHARMACEUTICALS, INC. reported in its quarterly report filed 2026-08-07 (fiscal Q2 2026): 42 published measures, 115 facts as tagged in accession 0001372514-26-000074.

This filing

Form
10-Q (quarterly report)
Filed
2026-08-07
Fiscal period
fiscal Q2 2026
Accession
0001372514-26-000074 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All KIORA PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2026-06-3023,776,090USD
At 2025-12-3124,253,300USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2026-06-306,919,401USD
At 2025-12-318,126,764USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2026-06-3016,856,689USD
At 2026-03-3113,934,561USD
At 2025-12-3116,126,536USD
At 2025-06-3022,127,476USD
At 2025-03-3123,700,385USD
At 2024-12-3125,759,776USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2026-06-307,076,533USD
At 2025-12-318,696,570USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-2,079,010USD91
2026-01-01 to 2026-06-30-4,496,994USD181
2025-04-01 to 2025-06-30-2,152,459USD91
2025-01-01 to 2025-06-30-4,345,439USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-5,053,267USD181
2025-01-01 to 2025-06-30-6,507,633USD181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2026-01-01 to 2026-06-3028,474USD181
2025-01-01 to 2025-06-3032,195USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2026-01-01 to 2026-06-304,917,989USD181
2025-01-01 to 2025-06-30265,359USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-1,488,155USD181
2025-01-01 to 2025-06-303,336,954USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2026-06-30-158,714,270USD
At 2025-12-31-154,217,276USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2026-04-01 to 2026-06-306,177,679shares91
2026-01-01 to 2026-06-305,181,693shares181
2025-04-01 to 2025-06-303,989,042shares91
2025-01-01 to 2025-06-303,936,649shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2026-04-01 to 2026-06-306,177,679shares91
2026-01-01 to 2026-06-305,181,693shares181
2025-04-01 to 2025-06-303,989,042shares91
2025-01-01 to 2025-06-303,936,649shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-0.34USD/shares91
2026-01-01 to 2026-06-30-0.87USD/shares181
2025-04-01 to 2025-06-30-0.54USD/shares91
2025-01-01 to 2025-06-30-1.1USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-0.34USD/shares91
2026-01-01 to 2026-06-30-0.87USD/shares181
2025-04-01 to 2025-06-30-0.54USD/shares91
2025-01-01 to 2025-06-30-1.1USD/shares181

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2026-04-01 to 2026-06-300USD91
2026-01-01 to 2026-06-300USD181
2025-04-01 to 2025-06-30-112,057USD91
2025-01-01 to 2025-06-3010,949USD181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2026-06-3099,637USD
At 2025-12-3191,672USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2026-01-01 to 2026-06-30318,820USD181
2025-01-01 to 2025-06-30411,390USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-2,213,771USD91
2026-01-01 to 2026-06-30-4,723,966USD181
2025-04-01 to 2025-06-30-2,396,196USD91
2025-01-01 to 2025-06-30-4,726,550USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2026-06-3021,262,515USD
At 2025-12-3121,748,448USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2026-06-302,370,495USD
At 2025-12-313,631,498USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2026-06-30216,497USD
At 2025-12-311,060,306USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2026-06-301,091,385USD
At 2025-12-311,522,770USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2026-04-01 to 2026-06-302,213,771USD91
2026-01-01 to 2026-06-304,723,966USD181
2025-04-01 to 2025-06-302,396,196USD91
2025-01-01 to 2025-06-304,726,550USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2026-04-01 to 2026-06-302,077,116USD91
2026-01-01 to 2026-06-304,200,841USD181
2025-04-01 to 2025-06-302,590,489USD91
2025-01-01 to 2025-06-305,122,376USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2026-06-304,427,167shares
At 2025-12-313,761,739shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2026-06-307,081,239USD
At 2025-12-318,701,136USD
At 2025-06-301,032,784USD
At 2024-12-313,796,379USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2026-06-30175,544,810USD
At 2025-12-31170,314,656USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2026-06-30-255,798USD
At 2025-12-31-246,137USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2026-06-30260,753USD
At 2025-12-31285,827USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2026-06-30333,022USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2026-06-302,063,100USD
At 2025-12-312,063,100USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2026-06-3085,379USD
At 2025-12-3159,687USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2026-06-301,981,573USD
At 2025-12-312,406,731USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2026-06-301,127,482USD
At 2025-12-311,141,804USD

Net deferred tax liabilities

Deferred tax liabilities net of related assets under this concept. The amount reflects timing differences and is not tax currently due.

PeriodValueUnitDays
At 2026-06-30102,152USD
At 2025-12-31102,152USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-2,079,010USD91
2026-01-01 to 2026-06-30-4,496,994USD181
2025-04-01 to 2025-06-30-2,264,516USD91
2025-01-01 to 2025-06-30-4,334,490USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2026-04-01 to 2026-06-301,383,504USD91
2026-01-01 to 2026-06-302,995,771USD181
2025-04-01 to 2025-06-301,353,850USD91
2025-01-01 to 2025-06-302,843,248USD181

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2026-01-01 to 2026-06-3021,304USD181
2025-01-01 to 2025-06-303,741USD181

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-11,471USD91
2026-01-01 to 2026-06-30-58,598USD181
2025-04-01 to 2025-06-30-93,557USD91
2025-01-01 to 2025-06-30-109,809USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2026-04-01 to 2026-06-30134,761USD91
2026-01-01 to 2026-06-30226,972USD181
2025-04-01 to 2025-06-30131,680USD91
2025-01-01 to 2025-06-30392,060USD181

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-431,384USD181
2025-01-01 to 2025-06-301,816,825USD181

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-681,518USD181
2025-01-01 to 2025-06-30509,579USD181

Inspect the source

Entity
KIORA PHARMACEUTICALS, INC. / CIK 0001372514
Captured
2026-09-20T07:57:09.611Z
SEC response SHA-256
3c8ad9197d1b760a7f418642919ba51ce1343d392d1a4d1fce0d72996117d019

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001372514.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))